Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4222476 | PMC |
| http://dx.doi.org/10.3324/haematol.2014.111872 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.
Crit Rev Oncol Hematol
January 2025
Department of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing 100070, China; Beijing Branch Center of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100070, China; Myeloma Research Institute, Beijing GoBroad Boren Hospital, Beijing 100070, China. Electronic address:
Article Synopsis
- Richter transformation poses a continued risk for chronic lymphocytic leukemia (CLL) patients, even with advancements in targeted therapies like Bruton's tyrosine kinase inhibitor, particularly in a reported case of a 61-year-old male who experienced this change post-treatment.
- After stopping ibrutinib during the COVID-19 pandemic, the patient developed a related plasmablastic lymphoma (PBL), diagnosed through histological analysis of a tumor in the supraclavicular area and bone marrow infiltration.
- The patient underwent treatment with a combination of CHP, venetoclax, and brentuximab vedotin, followed by successful BCMA CAR-T cell therapy, resulting in complete remission and highlighting the potential
Epstein-Barr virus-positive, primary cutaneous marginal zone lymphoma, with transformation: Case report and review of the literature.
Am J Clin Pathol
September 2024
Department of Pathology, Division of Dermatology, Department of Hematology and Hematopoietic Cell Transplantation, and Beckman Research Institute, City of Hope Medical Center, Duarte, CA, US.
Article Synopsis
- Epstein-Barr Virus (EBV) positive primary cutaneous marginal zone lymphoma (PCMZL) is rare and can transform into more aggressive forms, like plasmablastic lymphoma (PBL), which is often fatal.
- The case discussed involves a patient with multifocal PCMZL who experienced a sequence of transformations, eventually leading to disease progression and death, despite various treatments, with genetic mutations similar across lymphomas indicating a common origin.
- A review of 18 cases shows that nearly half of patients with transformed PCMZL succumbed to the disease, particularly those diagnosed with multiple disease sites, highlighting the poor prognosis associated with this transformation.
Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution.
Diagn Pathol
June 2024
Department of Pathology, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-Ro, Jongno-Gu, Seoul, 03080, Republic of Korea.
Background: Follicular lymphoma (FL) is characterized by t(14;18)(q32;q21) involving the IGH and BCL2 genes. However, 10-15% of FLs lack the BCL2 rearrangement. These BCL2-rearrangement-negative FLs are clinically, pathologically, and genetically heterogeneous.
View Article and Find Full Text PDFPlasmablastic myeloma transformation of light-chain multiple myeloma.
J Clin Exp Hematop
June 2024
Department of Pathology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
Plasmablastic myeloma (PBM) is an uncommon and aggressive morphologic variant of multiple myeloma (MM). The neoplastic immature cells exhibit diverse morphology, posing a diagnostic challenge. The diagnostic criteria for PBM include the identification of ≥ 2% plasmablasts in the bone marrow aspirate.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!